|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2007-10-8
|
|
pubmed:abstractText |
Exenatide was approved by the US Food and Drug Administration (FDA) in April 2005 as adjunctive therapy to metformin or a sulfonylurea for the treatment of type 2 diabetes mellitus (DM).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0149-2918
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2007 Excerpta Medica, Inc.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1784-94
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:17919559-Adult,
pubmed-meshheading:17919559-Blood Glucose,
pubmed-meshheading:17919559-Cohort Studies,
pubmed-meshheading:17919559-Diabetes Mellitus,
pubmed-meshheading:17919559-Diffusion of Innovation,
pubmed-meshheading:17919559-Drug Labeling,
pubmed-meshheading:17919559-Drug Prescriptions,
pubmed-meshheading:17919559-Drug Therapy, Combination,
pubmed-meshheading:17919559-Drug Utilization Review,
pubmed-meshheading:17919559-Female,
pubmed-meshheading:17919559-Guideline Adherence,
pubmed-meshheading:17919559-Humans,
pubmed-meshheading:17919559-Hypoglycemic Agents,
pubmed-meshheading:17919559-Insurance, Pharmaceutical Services,
pubmed-meshheading:17919559-Male,
pubmed-meshheading:17919559-Middle Aged,
pubmed-meshheading:17919559-Obesity,
pubmed-meshheading:17919559-Peptides,
pubmed-meshheading:17919559-Practice Guidelines as Topic,
pubmed-meshheading:17919559-Retrospective Studies,
pubmed-meshheading:17919559-Treatment Outcome,
pubmed-meshheading:17919559-United States,
pubmed-meshheading:17919559-United States Food and Drug Administration,
pubmed-meshheading:17919559-Venoms
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
|
|
pubmed:affiliation |
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. jsegal@jhmi.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Evaluation Studies
|
